NASDAQ$AVIR
Atea Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results and provided a business update.
Atea Pharmaceuticals reported a net loss of $31.3 million for the second quarter ended June 30, 2022, compared to a net income of $1.5 million for the quarter ended June 30, 2021. The company had $684.5 million in cash and cash equivalents as of June 30, 2022.
- Bemnifosbuvir is advancing to late-stage development for COVID-19 following meetings with the FDA and EMA.
- New data demonstrated bemnifosbuvir retained antiviral activity against Omicron subvariant in vitro.
- Progressing internal second-generation protease inhibitor discovery program for COVID-19 combination therapy.
- Enrolling AT-752 global Phase 2 trial and U.S. Human Challenge Study for Dengue.
Headline financials
Revenue & EPS history
Atea · Revenue · Quarterly
$60.4M
Forward guidance
Atea Pharmaceuticals is planning to initiate a global late-stage trial for bemnifosbuvir in Q4 2022 and expects initial results from AT-752 dengue trials in late 2022.
Tailwinds
- Initiate a global late-stage trial in the fourth quarter of 2022.
- Continue to progress our second-generation protease inhibitor discovery program.
- Expect initial results in late 2022 for AT-752.
- Preparing for the initiation of a Phase 2 combination study of bemnifosbuvir and ruzasvir, which is expected in late 2022.
- Remain well capitalized to advance our programs.
Headwinds
- COVID-19 continues to be a global emergency with waning efficacy from vaccines, therapeutics and prior infections driving an unmet medical need.
- Uncertainty around and costs associated with the clinical development of bemnifosbuvir as a potential treatment for COVID-19 and HCV.
- The primary endpoint, time to symptom alleviation, was not achieved in MORNINGSKY trial.
- Decrease in revenue of $60.4 million as a result of the termination of the Roche agreement.
- Net loss for the quarter ended June 30, 2022 was $31.3 million compared to net income of $1.5 million for the quarter ended June 30, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+0.1%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.2%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+16.1%
Q1 2021
Best reaction
-16.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | +11.1% | +15.1% | +8.7% | |
| Q3 2025 | -12.1% | -12.9% | -10.0% | |
| Q2 2025 | -2.6% | +1.2% | -2.6% | |
| Q1 2025 | +2.2% | +4.0% | +16.4% | |
| Q4 2024 | -0.3% | +3.3% | -7.0% | |
| Q3 2024 | -2.2% | -7.0% | -17.9% | |
| Q1 2024 | -8.2% | -9.7% | -8.4% | |
| Q4 2023 | -5.5% | -11.4% | -11.4% | |
| Q3 2023 | -10.7% | -14.0% | -10.1% | |
| Q2 2023 | +4.1% | +0.3% | -3.5% | |
| Q1 2023 | -1.2% | -3.0% | +35.8% | |
| Q4 2022 | -8.7% | -0.8% | -8.1% | |
| Q3 2022 | -12.4% | -14.4% | -24.0% | |
| Q2 2022 | -3.5% | -4.3% | -11.7% | |
| Q1 2022 | +12.9% | +36.8% | +52.7% | |
| Q4 2021 | +1.4% | -9.7% | +11.1% | |
| Q3 2021 | +6.5% | +6.5% | -25.3% | |
| Q2 2021 | -16.2% | -12.9% | -13.4% | |
| Q1 2021 | +16.1% | +18.7% | +20.4% | |
| Q2 2020 | +5.3% | -1.4% | -55.0% | |
| Q4 2020 | +5.3% | -1.4% | -55.0% | |
| Q1 2020 | +7.2% | +10.6% | +73.1% | |
| Q4 2019 | +7.2% | +10.6% | +73.1% | |
| Q3 2020 | +7.2% | +10.6% | +73.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro